Literatür Detay Bilgisi
Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma.

Yazarlar : Bhaskar A, Gupta R, Sreenivas V et al.

Yayın : Leuk Lymphoma.

Yayın Yılı : 2012

Pubmed Linki :

Konu : Myelom

Literatür İçeriği :  


Abstract Tumor angiogenesis is a complex process involving interplay of several angiogenic regulators. In the present study, mRNA expression and circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), hypoxia inducible factor (HIF)-1α, circulating endothelial progenitor cells (cEPC) and bone marrow microvessel density (MVD) were evaluated inmultiple myeloma (MM). Compared to healthy controls, the levels of VEGF, bFGF, Ang-2, HiF-1α and cEPC were significantly higher and Ang-1 and Ang-1/Ang-2 were lower in MM (p<0.01). The cEPC numbers correlated with Ang-1 (p=0.03), Ang-2 (p=0.01) and VEGF (p=0.002). On multivariate analysis, reduced Ang-1/Ang-2 ratio (p=0.005) at baseline was an independent predictor for response to therapy. After therapy, decrease in Ang-2 (p<0.001) and an increase in Ang-1/Ang-2 ratio (p=0.003) was observed in responders. This study highlights the role of angiopoietins in MM which may, thus, be evaluated as potential targets for anti-angiogenic therapy in future.

Literatür Arşivi

Konusu Aynı Olan Diğer Materyaller
SunumlarVideolarOlgu Tartışması